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Abstract
Background: Currently Norway does not recommend universal varicella vaccination for healthy children. This study
assessed susceptibility to varicella-zoster virus (VZV) in the Norwegian population for the first time.
Methods: A national convenience sample of residual sera was tested for anti-VZV IgG by ELISA. We estimated
age-specific seropositivity to VZV, controlling for sex and geographical distribution. We assessed differences
between the proportions using the chi-square test and multivariable logistic regression. Seroprevalence data were
compared to the varicella and herpes zoster-associated consultation rates in patients attending primary healthcare.
Results: Although 73.2 % (n = 1,540) of all samples were positive for VZV, only 11.2 % of samples collected from
1-year-olds were seropositive. There was a sharp increase in the proportion of seropositive in 3- and 5-year-olds
(40.2 % and 65.4 %, respectively). By the school entry age of 6 years, 69.8 % of children were seropositive. The
age-specific annual consultation rate for varicella in primary healthcare peaked in 1-year-olds, with 2,627 cases
per 100,000 population. The profile of varicella-related consultations in primary healthcare mirrored the VZV
seropositivity profile. The herpes zoster-related consultations in primary healthcare peaked in people over 70
years of age (702 cases per 100,000 population).
Conclusions: VZV seroprevalence in Norway was somewhat lower than in some other European countries. The
age-specific varicella–related consultation rates in primary healthcare mirrored the age profile of VZV
seroprevalence.
Background
Varicella-zoster virus (VZV) is a ubiquitous DNA virus
that belongs to the Herpesviridae family. The virus
spreads via airborne droplets and direct contact [1] and
causes varicella (chickenpox) and herpes zoster (shingles;
HZ) [1]. Varicella is a contagious childhood disease that
is usually benign [1]. However, an estimated 2–6 % of
varicella cases that seek care from a clinician develop
complications such as bacterial superinfections or
neurologic or pulmonary disorders [1, 2]. Although such
complications can occur in previously healthy children,
the risk is higher for adults [1]. The virus also establishes
latency in the neurons of sensory ganglia [3] and later, in
association with diminished VZV-specific cell-mediated
immunity, may reactivate causing HZ [4]. The lifetime
risk for HZ from natural infection is estimated to be
25 %, with most cases occurring in people over 50 years
of age and in immunocompromised individuals [5].
Safe and effective varicella vaccines have been available
since the 1970s [6], and vaccine against HZ is available
since 2006 [7]. Recently, a new candidate vaccine against
HZ has been developed as well [8]. However, despite
recommendations from the World Health Organization
(WHO) [9, 10] and the European Working Group on
Varicella [11], only some European countries have inte-
grated the varicella vaccine into national immunization
programs [12, 13]. There is a concern that universal
varicella vaccination may result in an increased inci-
dence of HZ due to the possible decline of exogenous
boosting following a reduced circulation of the wild type
virus [14]. In addition, high vaccination coverage is
needed to avoid shifting varicella morbidity to older age
groups [10]. In Norway, varicella vaccine is not currently
offered through the national immunization program, but
it is recommended for non-immune individuals [15] and
is fully reimbursed for those who are at risk of
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complications, such as people with immunodeficiencies
and stem cell transplantation patients [16]. Otherwise,
the vaccine is available at a cost per dose of 465 Norwe-
gian kroner (NOK) [17], which is roughly equivalent to
$57 USD. Based on the National Immunization Registry
SYSVAK, approximately 550 doses of varicella vaccines
are given to 450 individuals annually in Norway, with a
birth cohort of 60,000 children per year. There is cur-
rently no national recommendation regarding the use of
the HZ vaccine [18]. This vaccine has been licensed in
Norway since 2006 and is available at a cost of 1,748
NOK or roughly $220 USD per dose; approximately 100
doses have been sold since its licensure.
The availability of the varicella and HZ vaccines high-
lights the urgent need to assess the public health burden
of these diseases in Norway in order to inform national
vaccine policy decisions. Such an evaluation should be
supported by the assessment of VZV seroprevalence in
the population to understand the age-dependent dynam-
ics of the infection and to identify susceptible groups. In
Norway, few data about VZV seroepidemiology are avail-
able. All earlier studies focused on subsets of the popula-
tion, such as patients with multiple sclerosis, infectious
encephalitis, or pregnant women of foreign descent [19–
21]. Therefore, we examined the anti-VZV antibody
levels in different age groups in a sample of the Norwe-
gian population and identified population groups with
the lowest immunity against VZV. We also compared
seropositivity proportions with the age-specific consulta-
tions rates for varicella and HZ in patients attending pri-
mary healthcare.
Methods
Study design and data sources
This was a cross-sectional seroprevalence study con-
ducted using anonymized residual sera collected from
patients of all ages who sought either primary or hospital
care in Norway. Because all samples were anonymized,
reasons for healthcare visits and associated sample col-
lection are unknown. Laboratories however exclude
samples from known HIV and hepatitis cases. Sera speci-
mens are collected from all 19 counties throughout
Norway during a 5-week period each year, usually in
July–August. This study used residual sera obtained in
2006, 2007, 2008, 2011, and 2014 and excluded samples
collected during the influenza pandemic of 2009–2010.
The following information was available for each sample:
patient birth year, sex, county of residence, sample col-
lection date, and laboratory name.
The sample size in the study for each age group
was calculated using a 95 % confidence interval (95 %
CI) with a 10 % margin of error. As a result, roughly
100 samples were selected for each of the following
age groups: 1-year bands between 0 and 9 years; 5-
year bands between 10 and 49 years; 10-year bands
between 50 and 69 years; and 100 samples from those
70 years old and older. These age groups were chosen
to allow comparisons with data from other European
countries.
The sera were stored at −20 °C at the Norwegian Insti-
tute of Public Health where the testing was performed.
IgG antibody levels were measured using a commercial
indirect enzyme-linked immunosorbent assay (ELISA);
Enzygnost anti-VZV-IgG Virus/IgG, Siemens Healthcare
Diagnostics AS, Erlangen, Germany) with the automated
EVOLIS™ System from Bio-Rad and the DS2 Processing
System from DYNEX. According to the manufacturer,
the sensitivity of this method is 99.3 % and the speci-
ficity is 100 %. The assay was run in accordance with
the manufacturer’s instructions. The positive and
negative controls from the kit were used to validate
the assay and results. We had no kit independent
controls available. The cut-off for qualitative evalu-
ation of positivity was a corrected optical density
(OD) >0.2 at 450 nm. Samples with ODs <0.1 were
counted as negative, and samples with ODs between
0.1 and 0.2 were considered equivocal. Equivocal sam-
ples were not re-tested.
The rates of primary healthcare consultations asso-
ciated with varicella and HZ were measured using
health reimbursement data from 2008–2012 extracted
from the Norwegian Health Economics Administra-
tion database. The database includes individual reim-
bursement claims from all primary care providers in
Norway. The extracted data included all consultations
that had varicella or HZ at any diagnostic position,
coded as A72 and S70, respectively, according to the
International Classification of Primary Care, Second
Edition (ICPC-2). The age- and sex-specific rates per
100,000 population were calculated using the number
of primary care patients registered with varicella and
herpes zoster diagnoses for the first time during
2008–2012 as the nominator and population data for
the same time period as the denominator [22].
Data analysis
VZV seropositivity was estimated as a proportion with
the corresponding 95 % CI. We used the chi-square test
to examine differences in seropositivity by age, sex and
geographical regions. We also performed multivariable
logistic regression analysis to assess the association be-
tween VZV seroprevalence, which was classified as posi-
tive or negative, and a set of explanatory variables (sex,
age, geographic region). We assessed the fit of the differ-
ent models using likelihood ratio tests. Statistical signifi-
cance was set at a P-value <0.05. All analyses were
performed using the statistical software STATA, version
SE13 (StataCorp LP, College Station, TX, USA).
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Results
A total of 2,103 samples from patients aged 0 to 92 years
were included in the study, 51.9 % (n = 1,093) of which
were from males. Overall, 73.2 % (n = 1,540) of the sam-
ples were seropositive for VZV (Table 1). The propor-
tions of seropositive males and females were similar,
50.6 % and 49.4 %, respectively. The seropositivity pro-
portion in children under 1 year of age was 58.9 %. This
decreased to 11.2 % at the age of 1 year, likely reflecting
a short-lived immunity conferred by maternal antibodies
[23, 24]. The proportion of seropositive individuals in-
creased to 40.2 % and 65.4 % at 3 and 5 years of age, re-
spectively. By school entry age, which is 6 or 7 years old,
69.8 % and 71.4 % of children, respectively, were im-
mune to varicella. The proportion of immune children
increased further to 81.4 % by age 10–14 years (Fig. 1).
By age 20 years, 86.4 % of the Norwegian population
had acquired natural varicella immunity, and by age
35–39 years, 95.7 % of subjects had detectable anti-
VZV antibodies.
Females of childbearing age, defined as those aged 15
to 49 years old [25], accounted for 34 % of all samples
collected from women (343/1,010) and for 16.3 % of all
tested samples. Of these samples, the overall seropositivity
proportion was 88.6 %. The average proportion of sero-
negative females in this age group was 5.3 %. The propor-
tion of non-immune women was highest, 13 %, in young
adulthood (20–24 years); this proportion declined in the
older age groups.
We also assessed the VZV seroprevalence in seven
geographic regions defined by the population density
[22]. The seropositivity proportions ranged from 59 % in
sparsely populated central Norway to 86 % in densely
populated Southeast Norway. However, multivariable
analysis indicated that age group was the only explana-
tory variable that was significantly associated with VZV
seropositivity (Additional files 1 and 2).
From 2008–2012, there were a total of 73,065
varicella-related primary healthcare consultations by
56,134 persons in Norway, corresponding to an average an-
nual consultation rate of 231 cases per 100,000 population.
The highest consultation rate, 2,627 cases per 100,000
population, was observed in children aged 1 year; the low-
est consultation rate was found in patients ≥70 years old.
The varicella consultation rate in primary healthcare mir-
rored the VZV seroprevalence profile (Fig. 2), with children
under 10 years old accounting for 79.3 % of all varicella
cases. The majority of varicella patients (80 %) had only




% (No of samples) 95 % CI % (No of samples) 95 % CI % (No of samples) 95 % CI
0 y 58.9 (56) 48.8–68.4 29.5 (28) 21.1–39.4 11.6 (11) 6.5–19.8
1 y 11.2 (12) 6.5–18.8 86.9 (93) 79.1–92.1 1.9 (2) 0.5–7.2
2 y 16.3 (17) 10.4–24.8 77.9 (81) 68.9–84.9 5.8 (6) 2.6–12.3
3 y 40.2 (41) 31.1–50.0 55.9 (57) 46.1–65.2 3.9 (4) 1.5–10.0
4 y 48.5 (49) 38.9–58.2 50.5 (51) 40.8–60.2 1.0 (1) 0.1–6.8
5 y 65.3 (66) 55.5–74.0 33.7 (34) 25.1–43.5 1.0 (1) 0.1–6.8
6 y 69.8 (67) 59.8–78.2 26.0 (25) 18.2–35.8 4.2 (4) 1.6–10.6
7 y 71.4 (70) 61.7–79.5 24.5 (24) 17.0–34.0 4.1 (4) 1.5–10.4
8 y 82.8 (82) 74.0–89.1 15.2 (15) 9.3–23.7 2.0 (2) 0.5–7.8
9 y 78.1 (75) 68.7–85.3 16.7 (16) 10.4–25.5 5.2 (5) 2.2–12.0
10–14 y 81.4 (118) 74.2–86.9 11.7 (17) 7.4–18.1 6.9 (10) 3.7–12.4
15–19 y 89.5 (94) 82.0–94.1 4.8 (5) 2.0–11.0 5.7 (6) 2.6–12.2
20–24 y 86.4 (89) 78.3–91.8 8.7 (9) 4.6–16.0 4.9 (5) 2.0–11.2
25–29 y 90.0 (81) 81.8–94.7 10.0 (9) 5.3–18.2 0 (0) -
30–34 y 91.9 (79) 83.8–96.1 2.3 (2) 0.6–8.9 5.8 (5) 2.4–13.3
35–39 y 95.7 (90) 89.1–98.4 1.1 (1) 0.1–7.2 3.2 (3) 1.0–9.5
40–44 y 91.8 (89) 84.3–95.8 1.0 (1) 0.1–7.0 7.2 (7) 3.5–14.4
45–49 y 94.8 (91) 88.0–97.8 3.1 (3) 1.0–9.3 2.1 (2) 0.5–8.0
50–59 y 95.9 (94) 89.6–98.5 3.1 (3) 1.0–9.1 1.0 (1) 0.1–7.0
60–69 y 95.8 (91) 89.3–98.4 3.2 (3) 1.0–9.4 1.1 (1) 0.1–7.2
70+ y 93.7 (89) 86.6–97.1 1.1 (1) 0.1–7.2 5.3 (5) 2.2–12.1
Total 73.2 (1540) 71.3–75.1 22.7 (478) 21.0–24.6 4.0 (85) 3.3–5.0
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Fig. 1 Age-specific varicella-zoster virus seroprevalence as measured by serum IgG antibodies among a subset of Norwegian
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Fig. 2 Age-specific varicella-zoster virus seropositivity (serum IgG antibodies) and age-specific consultation rate (cases per 100,000 population) of
varicella and herpes zoster as first encounter with primary healthcare in Norway 2008–2012. The blue line represents percent of VZV seropositive
individuals as measured by serum IgG antibodies in a subset of Norwegian population (n = 2013). Orange line shows the number of varicella cases
per 100,000 population measured as first encounter with primary healthcare in Norway, 2008–2012 (n = 56,126). The pink line represents number
of herpes zoster cases per 100,000 population, measured as first encounter with primary healthcare in Norway, 2008–2012 (KUHR)
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one encounter in a primary healthcare setting, mostly with
GP (75 %). In 2008–2012, there were 124,139 HZ
consultations by 54,094 persons in Norway, translat-
ing to an average annual rate of 223 cases per
100,000 population. The highest HZ consultation rate
was observed in patients ≥70 years old (702 cases per
100,000 population), and the lowest rate was found in
children in their first year of life (5.6 cases per
100,000 population). Most HZ patients had one or
two encounters (76 %) with primary healthcare, and
the majority (80 %) were GP consultations.
Discussion
This is the first study to describe the age-specific sero-
prevalence of anti-VZV antibodies in different age
groups in a Norwegian population. Because the varicella
vaccine is currently used infrequently in Norway, we
documented the pre-vaccine seroepidemiology of VZV
and the use of primary healthcare associated with
varicella and HZ. Overall, 73.2 % of the Norwegian
population has natural immunity against varicella, with
the highest seropositivity, 95.7 %, found in adults 35–39
years of age, suggesting almost universal transmission of
VZV infection. Varicella-related consultation rates in
primary healthcare mirrored VZV seroprevalence, with a
peak in children aged 1 year. This pattern suggests a
possible correlation between these different measures of
varicella occurrence. For HZ, the opposite pattern was
observed, prompting further investigation of the factors
that influence the occurrence of this disease in Norway.
Similar to other European countries, varicella immun-
ity in Norway is acquired gradually, starting in early
childhood and showing a sharp increase around age 3–5
years. By this age, 90 % of Norwegian children have en-
tered organized childcare [26], thereby increasing their
opportunities for varicella exposure. By the school entry
age of 6 years, 7 of 10 children are already immune, and
an additional 10 % acquire natural immunity by age
10 years. The latter is somewhat lower than findings in
other Nordic countries. For comparison, 91 % of chil-
dren are reported to be seropositive by age 10 years in
Finland [27], and in Sweden, 98 % of 9–12-year-olds are
immune to varicella [28]. This is higher than the 78 %
found in the same age group in our study, and there is
no clear explanation for the difference. The 12 % of sus-
ceptible individuals aged 10–14 years in Norway is
higher than the 8.3 % found in the same age group in
Spain [27] or in Poland, where 82 % are seropositive by
the age of 10 years [29]. We also found somewhat higher
proportions of susceptibility in young children and ado-
lescents compared to other countries, e.g. England and
Wales, Belgium, Israel, Ireland, Netherlands, Slovakia
[27], and Poland [29]. In Europe, VZV seroprevalence
differs by country. Although, a standardized VZV
seroprevalence study in 11 European countries demon-
strated that over 90 % of children are VZV seropositive by
age 15 years in most of the countries [27], for 5-year-old
children, the lowest proportions of seropositive individuals
were found in Italy (38 %) [27] and Poland (48 %) [29],
and the highest proportion was found in the Netherlands
(95–97 %) [30].
In our study, the proportion of susceptible adults aged
20–29 years was 9.5 %, whereas in most other European
countries, this proportion is less than 5 %, except in Italy
(11.5 %), the UK (7.1 %), Spain (6.9 %), and Ireland
(6.2 %) [27]. Among females of childbearing age (15–49
years) in Norway, the proportion of non-immune sub-
jects was 5.3 %. Nardone et al. reported such proportion
to be less than 5 % in most European countries, except
for Ireland (5.4 %) and Italy (12.5 %) [27]. The results of
Nardone et al. are not directly comparable to our
findings due to their use of a slightly different age group
(15–39 years). It is difficult to compare our results with
countries that were not included in the study by
Nardone et al. due to methodological differences and
variations in the age groups.
The level of IgG antibodies in a single sample may
vary in different assays. A high percentage of equivocal
samples detected in young adults in our study may
therefore partly be due to the assay chosen for the study,
for which international standards were not used.
Differences in VZV seropositivity levels in different
European countries can be explained in part by varying
population densities and social mixing patterns in the
countries and perhaps by climate differences. However,
it is surprising that VZV seropositivity in the children
and adults in our study was somewhat lower than in re-
ports from other Nordic countries with comparable pop-
ulations and climates. It is possible that our results were
somewhat affected by the convenience sampling used in
the study. Such sampling is subject to selection bias be-
cause residual samples are collected from people seeking
medical help, limiting the generalizability of the results.
Despite these limitations, this method is often preferred
in seroepidemiological studies over more generalizable
population-based probability sampling. Convenience
sampling is less costly and time-consuming, and the
samples are easier to obtain [31]. Moreover, the VZV
seroprevalence as estimated by convenience sampling is
shown to be similar to the results of studies that use
population-based cluster sampling [32]. To increase
study validity, we collected samples from all geographic
regions in the country and selected sera only from large
microbiological laboratories that test patients who re-
ceive both primary and hospital healthcare. All residents
in Norway have universal access to healthcare, so it is
possible that our data included individuals who visited a
healthcare provider for prophylactic purposes.
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We found high seropositivity in infants (58.9 %), but
this dropped sharply to 11.2 % by age 1 year, which may
be explained by waning maternal antibodies [23, 24, 33].
In children aged one year, the proportion of seropositive
subjects in our study was similar to the proportions in
Finland, Italy, and Spain. However, in the majority of
other European countries, the proportions are higher,
varying between 20 % and 40 % [27]. Nevertheless, the
actual age at sample collection in our study was not
available; thus, the year of birth was subtracted from the
year of sample collection, which could have affected the
results for children under one year of age. Given that
samples are collected in July–August of each year, the
age group that was under one year of age in our sample
was composed of children aged 0 to 8 months, whereas
the one-year age group included children aged 7 to
20 months. This age distribution could result in overesti-
mation of seropositivity in those under one year of age
and underestimation of seropositivity in those older than
one year. With increasing age, this difference would not
have such a dramatic effect on seropositive proportions.
However, this could be only verified if the actual age was
reported rather than just the year of birth.
Our sample size was estimated to allow a detailed as-
sessment of seroprevalence in children because we ex-
pected high seropositivity in adults. Although the total
number of samples in our study (n = 2,103) was similar
to the number of samples used in other European
studies, we had fewer samples per age group in adults
compared to, for example, the study by Nardone et al.
(100 vs. 200 samples per 5-year age band) [27, 34]. Since
we used anonymized sera, we cannot determine the
number of samples that were collected from people who
originate from tropical and subtropical countries, where
lower varicella immunity in adolescents and young
adults is established [35]. Since the 1990s, the estimated
proportion of people of foreign descent in Norway has
increased to 13 %, of which about one-third (26 %) ori-
ginate from Asia [22]. A similar pattern is reported in
Sweden [36] but not in Finland (3 %) [37], suggesting
that the higher seroprevalence among Swedish children
compared to our findings could be due to the timing of
sample collection. Samples in Sweden as well as in
Finland were collected in 1997–1998 when the propor-
tion of immigrants was considerably lower than in 2006
and later when there were higher proportions of people
of foreign descent in Norway. Therefore, the probability
of samples being collected from people originating from
settings that have shown differences in their varicella
epidemiology may be higher in Norway than in other
Nordic countries. In the Netherlands, being a foreign
national was associated with lower VZV seropositivity in
children under 6 years old [30], and more seronegative
adults were found to originate from tropical and
subtropical countries [35, 38]. Since ethnicity data were
not available for this study, this hypothesis requires fur-
ther research.
The differences between geographical regions found in
our study should be interpreted with caution. Sampling
bias may minimize the study’s power to find differences
since the study was designed primarily to measure VSV
seroprevalence in different age groups on the national
level, not on the regional level. We found that 5.3 % of
women of childbearing age were susceptible to VZV.
This proportion was even higher in those aged 20–24
(13 %) and 25–29 years old (11 %). This is a potential
concern because women in these age groups give birth
to 45 % of the infants born annually in Norway. VZV in-
fection during pregnancy can lead to serious complica-
tions, such as maternal pneumonia and congenital
varicella syndrome [1]. However, these findings should
also be interpreted with caution because they, too, could
be affected by sampling bias. Since women born outside
of Norway may lack immunity to varicella, more evidence
is needed to define the groups for pregnancy screening in
order to reduce the risk of potential VZV complications.
Overall, the primary healthcare consultation rate of
both varicella and HZ was lower in Norway than in
other European countries [34]. However, a direct
comparison with other studies is very difficult due to dif-
ferences in methodology as well as varying VZV epi-
demiology from country to country. We found a similar
varicella consultation rate in Canada in a study by
Brisson et al. [39] that use a similar data source (the
physician billing claims); however, that study used data
from 1979–1997. The consultation rate in our study was
calculated using information on reimbursement claims
from primary care providers. It is thus unlikely that the
consultation rate was greatly underestimated because
healthcare is generally easily accessible to all Norwegian
residents. However, it may be somewhat underestimated,
as patients with mild symptoms, and for example add-
itional family members with infection may not seek
medical help. In addition, the disease could be misclassi-
fied due to atypical presentation. We observed a peak in
the consultation rate of varicella-related primary care
consultations around 1 year of age. This is the age at
which children are likely to be susceptible due to loss of
protection conferred by maternal antibodies, and this is
supported by our seroprevalence curve. However, it is
difficult to determine whether this increase represents a
true increase in the varicella incidence in the general
population or whether this peak reflects an increase in
more severe cases that have complications requiring
medical help. It is also possible that the increase is af-
fected by healthcare-seeking behavior since parents may
be more likely to seek medical help when a young child
contracts varicella.
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A high proportion of susceptibles in certain age groups
detected in our study underlines a need to revise Norwe-
gian varicella vaccine recommendations such as expand-
ing current recommendations to include adolescents
aged 10–15 years without a positive history of varicella.
There is also a need to consider varicella screening in
pregnancy to identify non-immune women to be tar-
geted for vaccination after giving birth. Such recommen-
dations may potentially reduce the proportion of
susceptible individuals at older ages and reduce the risk
of complications.
Conclusions
The VZV seroprevalence in Norway was somewhat
lower than in some other European countries. The age-
specific varicella-related consultation rates in primary
healthcare mirrored the age profile of VZV seropreva-
lence. These data lay the ground for further research to
quantify the disease burden of varicella and HZ and pre-
dict the impact of potential vaccination programs
through mathematical modeling.
Additional files
Additional file 1: Univariate and multivariable analysis of varicella-zoster
virus seropositivity by sex (reference: female), age group and region (ref-
erence: Oslo and Akershus) in Norway (odds ratios (OR), 95 % confidence
intervals (95 % CI), and p-value). (XLSX 12 kb)
Additional file 2: Model fitting information (Likelihood ratios and 95 %
confidence intervals (CI)). (S: Sex; R: region; A: age groups. Df: the number
of parameters that differ between the two nested models; AIC: Akaike
information criterion). (XLSX 10 kb)
Abbreviations
ELISA, enzyme-linked immunosorbent assay; HZ, Herpes zoster; IgG,
immunoglobulin G; VZV, varicella-zoster virus
Acknowledgements
The authors acknowledge Professor Piero Manfredi from the University of
Pisa, Department of Economics and Management for the valuable
discussions and comments to this manuscript.
Funding
The study was fully funded by the Norwegian Institute of Public Health.
Availability of data and materials
The dataset supporting the conclusions of this article cannot be shared per
national data protection legislation.
Authors’ contributions
GR conducted data analysis and drafted the manuscript. MG implemented
sample testing. BVS contributed to the statistical analysis and helped to draft
the manuscript. EF and KV conceived and designed the study and drafted
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by the Regional Committee for Medical and Health
Research Ethics, Oslo, Norway, as well as an exemption from patient’s
consent to use residual sera. The de-identified samples were obtained from
the biobank at the Norwegian Institute of Public Health following the in-
ternal procedures and approval from the Regional Committee for Medical
and Health Research Ethics, Oslo, Norway.
Received: 20 October 2015 Accepted: 14 May 2016
References
1. Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544):1365–76.
2. Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou
V, Rentier B, Rumke H, Sadzot-Delvaux C, Senterre J, et al. Varicella
vaccination in Europe - taking the practical approach. BMC Med. 2009;7:26.
3. Gershon AA, Chen J, Davis L, Krinsky C, Cowles R, Reichard R, Gershon M.
Latency of varicella zoster virus in dorsal root, cranial, and enteric ganglia in
vaccinated children. Trans Am Clin Climatol Assoc. 2012;123:17–33.
4. Arvin AM, Moffat JF, Redman R. Varicella-zoster virus: aspects of
pathogenesis and host response to natural infection and varicella vaccine.
Adv Virus Res. 1996;46:263–309.
5. Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines.
2010;9(3 Suppl):21–6.
6. Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N,
Stefkovicova M, Usonis V, Wysocki J, Douha M, et al. Protection against varicella
with two doses of combined measles-mumps-rubella-varicella vaccine versus
one dose of monovalent varicella vaccine: a multicentre, observer-blind,
randomised, controlled trial. Lancet. 2014;383(9925):1313–24.
7. European Medicines Agency, EMEA: Zostavax. European Public Assessment
Report. Summary of product characteristics. 2009. www.emea.europa.eu.
Accessed 22 May 2013.
8. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ,
Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, et al. Efficacy of an
Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. N Engl J Med.
2015;372(22):2087–96.
9. WHO. Varicella vaccines. WHO position paper. Wkly Epidemiol Rec. 1998;
73(32):241–8.
10. WHO. Varicella and herpes zoster vaccines: WHO position paper. Wkly
Epidemiol Rec. 2014;89(25):265–87.
11. Rentier B, Gershon AA. European Working Group on V. Consensus: varicella
vaccination of healthy children–a challenge for Europe. Pediatr Infect Dis J.
2004;23(5):379–89.
12. Carrillo-Santisteve P, Lopalco PL. Varicella vaccination: a laboured take-off.
Clin Microbiol Infect. 2014;20 Suppl 5:86–91.
13. The European Centre for Disease Prevention and Control. Vaccine Schedule. http://
vaccine-schedule.ecdc.europa.eu/pages/scheduler.aspx. Accessed 06 Oct 2014.
14. Ogunjimi B, Van Damme P, Beutels P. Herpes Zoster Risk Reduction through
Exposure to Chickenpox Patients: A Systematic Multidisciplinary Review.
PLoS One. 2013;8(6), e66485.
15. Norwegian Institute of Public Health. Varicella and herpes zoster vaccination
(2014). http://www.fhi.no/eway/default.aspx?pid=239&trg=Content_
6493&Main_6157=6287:0:25,5501&MainContent_6287=6493:0:
25,6826&Content_6493=6441:68714::0:6446:26:::0:0. Accessed 26 March 2015.
16. Ministry of Health and Care Services of Norway. Reimbursement Prescription
Regulations (Blåresept-forskriften). 2007. https://lovdata.no/dokument/SF/
forskrift/2007-06-28-814. Accessed 05 Aug 2015.
17. Norwegian Medicines Agency. Varilrix. http://www.legemiddelverket.no/
Legemiddelsoek/Sider/Legemiddelvisning.aspx?pakningId=0a170bc8-797f-
4503-8377-941c07736cca&searchquery=varilrix&f=Han;MtI;Vir;ATC;Var;Mar;
Mid;Avr&pane=0. Accessed 22 Apr 2015.
18. Tseng HF, Liu A, Sy L, Marcy SM, Fireman B, Weintraub E, Baggs J, Weinmann S,
Baxter R, Nordin J, et al. Safety of zoster vaccine in adults from a large managed-
care cohort: a Vaccine Safety Datalink study. J Intern Med. 2012;271(5):510–20.
19. Quist-Paulsen E, Kran AM, Dunlop O, Wilson J, Ormaasen V. Infectious
encephalitis: a description of a Norwegian cohort. Scand J Infect Dis. 2013;
45(3):179–85.
20. Myhr KM, Riise T, Barrett-Connor E, Myrmel H, Vedeler C, Gronning M, Kalvenes
MB, Nyland H. Altered antibody pattern to Epstein-Barr virus but not to other
herpesviruses in multiple sclerosis: a population based case–control study from
western Norway. J Neurol Neurosurg Psychiatry. 1998;64(4):539–42.
Rimseliene et al. BMC Infectious Diseases  (2016) 16:254 Page 7 of 8
21. Bjerke SE, Vangen S, Holter E, Stray-Pedersen B. Infectious immune status in
an obstetric population of Pakistani immigrants in Norway. Scand J Public
Health. 2011;39(5):464–70.
22. Statistics Norway. Population statistics. http://www.ssb.no/befolkning.
Accessed 26 Mar 2015.
23. Heininger U, Desgrandchamps D, Schaad UB. Seroprevalence of Varicella-
Zoster virus IgG antibodies in Swiss children during the first 16 months of
age. Vaccine. 2006;24(16):3258–60.
24. Koskiniemi M, Lappalainen M, Schmid DS, Rubtcova E, Loparev VN.
Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland.
Clin Vaccine Immunol. 2007;14(9):1057–61.
25. Norwegian Institute of Public Health. Fruktbarhet, fødealder og helse -
faktaark med statistikk. 2015. http://www.fhi.no/artikler/?id=67742. Accessed
8 May 2015.
26. The Norwegian Directorate for Education and Training. Norske barnehager i
tall. 2013. http://www.udir.no/Upload/barnehage/Forskning_og_statistikk/
Statistikk/US2013_barnehager.pdf?epslanguage=no. Accessed 17 Oct 2014.
27. Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota
MC, de Melker H, Mossong J, Slacikova M, et al. The comparative sero-
epidemiology of varicella zoster virus in 11 countries in the European
region. Vaccine. 2007;25(45):7866–72.
28. Svahn A, Berggren J, Parke A, Storsaeter J, Thorstensson R, Linde A. Changes
in seroprevalence to four herpesviruses over 30 years in Swedish children
aged 9–12 years. J Clin Virol. 2006;37(2):118–23.
29. Siennicka J, Trzcinska A, Rosinska M, Litwinska B. Seroprevalence of varicella-
zoster virus in Polish population. Przegl Epidemiol. 2009;63(4):495–9.
30. van Lier A, Smits G, Mollema L, Waaijenborg S, Berbers G, van der Klis F,
Boot H, Wallinga J, de Melker H. Varicella zoster virus infection occurs at a
relatively young age in The Netherlands. Vaccine. 2013;31(44):5127–33.
31. Bornstein MH, Jager J, Putnick DL. Sampling in Developmental Science:
Situations, Shortcomings, Solutions, and Standards. Dev Rev. 2013;33(4):357–70.
32. Kelly H, Riddell MA, Gidding HF, Nolan T, Gilbert GL. A random cluster
survey and a convenience sample give comparable estimates of immunity
to vaccine preventable diseases in children of school age in Victoria,
Australia. Vaccin. 2002;20(25–26):3130–6.
33. Waaijenborg S, Hahne SJ, Mollema L, Smits GP, Berbers GA, van der Klis FR,
de Melker HE, Wallinga J. Waning of maternal antibodies against measles,
mumps, rubella, and varicella in communities with contrasting vaccination
coverage. J Infect Dis. 2013;208(1):10–6.
34. Helmuth IG, Poulsen A, Suppli CH, Molbak K. Varicella in Europe-A review of the
epidemiology and experience with vaccination. Vaccine. 2015;33(21):2406–13.
35. Akram DS, Qureshi H, Mahmud A, Khan AA, Kundi Z, Shafi S, Rehman Nu,
Olowokure B, Weil J, Bock H, et al. Seroepidemiology of varicella-zoster in
Pakistan. Southeast Asian J Trop Med Public Health. 2000;31(4):646–9.
36. Statistics Sweden. Sveriges framtida befolkning 2015–2060. 2015. http://
www.scb.se/Statistik/_Publikationer/BE0401_2015I60_BR_BE51BR1502.pdf.
Accessed 12 May 2015.
37. The Ministry of the Interior of Finland. Annual report on immigration. 2009,
2012. http://www.migri.fi/download/46518_46515_Maahanmuuton_
tilastokatsaus_2012_ENG_web.pdf?e251abcb8449d288. Accessed 12 May 2015.
38. van Rijckevorsel GG, Damen M, Sonder GJ, van der Loeff MF, van den Hoek
A. Seroprevalence of varicella-zoster virus and predictors for seronegativity
in the Amsterdam adult population. BMC Infect Dis. 2012;12:140.
39. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De
Serres G. Epidemiology of varicella zoster virus infection in Canada and the
United Kingdom. Epidemiol Infect. 2001;127(2):305–14.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Rimseliene et al. BMC Infectious Diseases  (2016) 16:254 Page 8 of 8
